Abstract:Abstract Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have poor outcomes with the available strategies. Based on the promising results seen in patients treated with anti-CD19 CAR T-cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma, we initiated a phase 1 study to evaluate the safety and efficacy in patients. Autologous T cells were genetically modified to express a chimeric antigen receptor consisting of an anti-CD19-scFv domain with CD3ζ and 4–1BB signalling domains. Methods We did this phase 1 study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma in Peking University Cancer Hospital, Beijing, China. Patients received a CAR T-cell infusion after a conditioning regimen of cyclophosphamide (250 mg/m 2 ) and fludarabine (25 mg/m 2 ) daily for 3 days. Three CAR T cell doses were tested: 5 × 10 4 CAR T cells/kg, 1 × 10 5 CAR T cells/kg, and 1 × 10 6 CAR T cells/kg. Primary endpoints included safety and pharmacokinetics of CAR T cells. Secondary endpoints include complete response, overall response, and duration of response per International Working Group Criteria. This trial is registered at ClinicalTrials, number NCT02842138. Findings As of March 2017, 14 patients were enrolled and ten patients, with a median age of 37 years (range 24–68) underwent response evaluation. Of the ten evaluable patients, four were women, six were men, three had follicular lymphoma, and seven had diffuse large B-cell lymphoma. The median number of previous therapies was 2·5 (range 2–7). The first group of three patients (two with follicular lymphoma and one with diffuse large B-cell lymphoma) received 5 × 10 4 CAR T cells/kg. Two patients with follicular lymphoma achieved partial remission on day 28, and one of these patients achieved complete remission 3 months later. The second group of three patients (one with follicular lymphoma and two with diffuse large B-cell lymphoma) received 1 × 10 5 CAR T cells/kg. The patient with follicular lymphoma achieved partial remission on day 28. The last group of four patients (all were diagnosed with diffuse large B-cell lymphoma) received 1 × 10 6 CAR T cells/kg. Three patients (75%) achieved partial remission on day 28. One patient attained progressive disease on day 28, and died 10 days later due to disease progression. A significant CAR T-cell expansion was detected in this case. On day 26, 26·8% of the patientu0027s peripheral blood mononuclear cells were CAR T cells. PD1 expression was significant in her expanded CAR T cells. 78·3% of CD8-positive CAR T cells and 71·4% of CD4-positive CAR T cells expressed PD1 on day 26, as compared with 22% and 42% on day 13, respectively in the same patient. Increased PD1-expressing CAR T cells were also found in other patientsu0027 peripheral blood. No serious adverse event was observed in any patient. Two patients had mild fever (grade 1–2). In-vivo expansion of CAR T cells was detected in all patients between day 14–28. All responding patients were still in remission at the last follow-up (range 2·5–9·0 months). Interpretation This study demonstrated early promising activity of anti-CD19 CAR T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The toxicities of cytokine release syndrome were mild and manageable. Our study also provided the first clinical evidence that expanded CAR T cells could express PD1. Blocking PD1 pathway might enhance the effector function of CAR T cells and improve the clinical outcomes of CAR T-cell therapy. Funding Marino Biotechnology Co, Ltd.

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19+ Tumor Cells

Efficacy and Safety of Adoptive Immunotherapy Using Anti-Cd19 Chimeric Antigen Receptor Transduced T-cells: a Systematic Review of Phase I Clinical Trials.

Evaluation of <i>piggyBac</i> ‐mediated anti‐CD19 CAR‐T cells after ex vivo expansion with aAPCs or magnetic beads

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Abstract 3294: In vivo delivery of a novel CD3-targeted lentiviral vector generates CD19 CAR-T cells in two different humanized mouse models and results in complete B cell depletion

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report

Abstract 7239: Eradication of B cell lymphoma in a mouse model through in vivo transduction of T cells with an aCD19-CAR utilizing a CD3-targeted lentiviral vector

Abstract A024: Systemic administration of CD3-redirected lentiviral vector efficiently targets CD19-CAR delivery to human T cells in vivo

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models

Differences in the Phenotypes and Transcriptomic Signatures of Chimeric Antigen Receptor T Lymphocytes Manufactured Via Electroporation or Lentiviral Transfection

The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies

Pharmacokinetic and Pharmacodynamic Studies of CD19 CAR T Cell in Human Leukaemic Xenograft Models with Dual-Modality Imaging.

Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Abstract B64: Coexpression of a CD19-OX40-CD3ζ CAR with Membrane-Bound IL-15 Enhances Natural Killer Cell Function

Abstract 2918: In vivo delivery of CD3-directed CD19-CAR lentivectors leads to the generation of CAR T and NK-like (CAR-TaNK) cells capable of complete ablation of B cells in the blood, bone marrow, and tissue of NSG-SGM3 CD34+ humanized mice

[Construction and Evaluation of Dual-Effect Cord Blood Natural Killer Cells Expressing Highaffinity PD-1 and Chimeric Antigen CD19 Receptor].

Distribution of Chimeric Antigen Receptor-Modified T Cells Against CD19 in B-cell Malignancies

Development of Novel Humanized CD19/BAFFR Bicistronic Chimeric Antigen Receptor T Cells with Potent Antitumor Activity Against B-cell Lineage Neoplasms.

Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor